UK News Bayer examines the production of corona vaccines

11:15  17 january  2021
11:15  17 january  2021 Source:   pressfrom.com

GPs told to 'stand down' routine care and focus on Covid vaccinations

  GPs told to 'stand down' routine care and focus on Covid vaccinations It is hoped the new battle plan will bolster the UK's sluggish vaccination programme and boost chances of immunising 13million people and ending lockdown by March. So far the country's vaccination programme has been plagued by supply and staffing shortages, logistical problems and bureaucratic barriers that have strangled its scale-up. It has meant that only 1.3million Brits have had the jab since it launched a month ago.Figures today showed that the NHS in England has now managed to inoculate almost 1.1million people since the mass immunisation drive began, dishing out more than 300,000 doses last week.

Corona Ticker. We are contributing to the global fight against the coronavirus through our products and expertise in health and nutrition. 13:30 p.m. CEST: How can Bayer support the production of a possible vaccine against the coronavirus? "We will provide support in terms of the requisite additional

Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a At least 90 preclinical vaccines are under active investigation in animals. New additions and recent updates. The company is aiming for production of a billion doses in 2021.

The pharmaceutical company Bayer is considering starting the production of corona vaccines. "We are discussing with Curevac and also with politicians and the authorities what can be done," says Bayer boss Werner Baumann of "Welt am Sonntag".

Bayer-Chef Werner Baumann in Leverkusen. © Oliver Berg / dpa Bayer boss Werner Baumann in Leverkusen.

“With our production network in Germany and the USA and the corresponding lead time, we would be basically able to produce vaccine in larger quantities. We are currently testing this under high pressure. " It is not primarily about financial considerations, but about making the vaccine available as soon as possible.

Poor countries will receive vaccines in the coming weeks, promises WHO

 Poor countries will receive vaccines in the coming weeks, promises WHO © AFP / Fabrice COFFRINI The international Covax program, launched by WHO with the support of the Alliance for Vaccines (Gavi) should make it possible to procure two billion doses of vaccine.

The vaccinations are expected to produce antibodies against spike proteins of SARS-CoV-2. It must be absolutely ruled out that a vaccine against SARS-CoV-2 could trigger an immune reaction against syncytin-1, as otherwise infertility of indefinite duration could result in vaccinated women .

Monsanto's merger with Bayer , the international chemical and pharmaceutical company most famous for producing Aspirin, is the largest-ever foreign takeover bid from a German company. Both companies produce pesticides, and together would control 28 percent of the global pesticide market.

At the beginning of the month, Bayer and the Tübingen biotech company Curevac signed a cooperation and service agreement. Curevac has been working on the development of the corona vaccine CVnCoV for a long time, for which the approval-relevant clinical phase III study began in mid-December. Curevac expects the first results towards the end of March. In the event of approval, the EU Commission has secured 405 million doses for the EU states.

Bayer should now participate in the necessary study during approval work and also keep an eye on the supply chains. The contract does not include the fact that the group will also take over production. In addition, Curevac remains the holder of a marketing authorization. Bayer would, however, have the option of becoming a holder of the approval in certain markets outside of Europe.

Technology used to ‘protect’ Pfizer vaccine originated in UK nearly 50 years ago .
Professor Gregory Gregoriadis discovered that encasing vaccines within tiny spherical bubbles of fat could increase their effectiveness.Biochemist Gregory Gregoriadis, professor emeritus at University College London, was one of the two scientists who discovered that encasing vaccines within tiny spherical bubbles of fat – known as liposomes – could increase their effectiveness by producing more antibodies.

usr: 0
This is interesting!